Last edition
News about "Gilead Sciences"
Gilead Sciences Opens 182,000-Sq-Ft Research Centre at Foster City Headquarters
Gilead Sciences has opened a 182,000-square-foot research centre in Foster City, expanding its capabilities in oncology, inflammation and research data science.
Gilead Sciences | 10/09/2026 | By News Bureau
Gilead Opens State-of-the-Art Research Center to Advance Next Generation Medicines
Gilead opens a new research center in Foster City, bringing together oncology, inflammation and data science teams to advance next-generation medicines.
Gilead Sciences | 09/09/2026 | By News Bureau | 212
US FDA Approves Gilead's Bixlenvo for Once-Daily HIV Treatment
The US Food and Drug Administration (FDA) approves Gilead’s Bixlenvo, a once-daily single-tablet HIV treatment combining bictegravir and lenacapavir for virologically suppressed adults.
Gilead Sciences | 01/09/2026 | By News Bureau
EU Expands Trodelvy Use in First-Line Metastatic Triple-Negative Breast Cancer
The European Commission (EC) approves Trodelvy plus pembrolizumab for first-line PD-L1-positive metastatic Triple-Negative Breast Cancer (TNBC), expanding its use across PD-L1 status.
Gilead Sciences | 25/08/2026 | By News Bureau | 102
The European Commission has approved Trodelvy for first-line treatment of unresectable or metastatic triple-negative breast cancer, offering a new therapeutic option for patients with one of the most aggressive forms of breast cancer.
Gilead Sciences | 25/06/2026 | By News Bureau | 137
US FDA Accepts Gilead's Once-Weekly Yeztugo for HIV Prevention
Gilead’s investigational once-weekly oral HIV prevention pill Yeztugo has been accepted for US FDA review, supported by strong clinical data showing high efficacy of lenacapavir in preventing HIV across 2 clinical trials. The therapy could become the first long-acting oral option for HIV prevention.
Gilead Sciences | 16/06/2026 | By News Bureau | 167
Gilead and Merck Report Positive Phase 3 Results for Weekly HIV Pill
Gilead and Merck reported positive phase 3 results for the investigational once-weekly oral HIV therapy islatravir/lenacapavir, which has the potential to become the first approved long-acting weekly oral treatment for people living with HIV.
Gilead Sciences | 09/06/2026 | By News Bureau | 138
Gilead Sciences Wins FDA Accelerated Approval for First HDV Treatment Hepcludex
Gilead Sciences receives Food and Drug Administration (FDA) accelerated approval for Hepcludex, the first and only approved treatment for chronic Hepatitis Delta Virus (HDV), addressing a major unmet need in severe viral hepatitis care.
Gilead Sciences | 26/05/2026 | By News Bureau | 112
Gilead Sciences and Kite Pharma to present new ASCO and EHA 2026 data highlighting progress in Antibody Drug Conjugates (ADCs) and CAR T-cell therapies, including updates on Trodelvy and anito-cel for difficult-to-treat cancers.
Gilead Sciences | 22/05/2026 | By News Bureau | 651
Gilead Sciences Completes Arcellx Inc. Acquisition Ahead of Anito-cel Launch
Under the terms of the transaction, Gilead acquired Arcellx for USD 115 per share in cash, plus one non?transferable Contingent Value Right (CVR) of USD 5 per share, representing a total implied equity value of approximately USD 7.8 billion at the time of closing.
Gilead Sciences | 29/04/2026 | By News Bureau | 200
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy